“Perhaps the most important aspect of this trial is the safety, especially with all of the controversy about cardiovascular concerns,” Dr. Brock said. “There was no evidence of cardiovascular events in the treated arm and a single ischemic stroke in the placebo arm among the 356 patients in that group.”
Dr. Brock and his colleagues found that testosterone solution 2% therapy in hypogonadal men resulted in TT levels returning to the normal range in most of the cases. The testosterone solution also led to statistically significant improvements in sex drive and energy levels.
“The safety in this study was clear, and as a result, I think this is an important study that gives us new insight into the treatment of the hypogonadal male,” he asserted.
This study was funded by Eli Lilly. Dr. Brock has served as a consultant, done research in clinical trials, and served on advisory boards for several pharmaceutical companies. He owns stock in Lilly, in addition to Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Astellas Pharma.